BB-401

N/A

Report date: 2025/04/20 20:00:03

NME

Base Information

Drug NameBB-401

Drug Alias NameBB-401

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsSquamous Cell Carcinoma of Head and Neck

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian FederationAustralia

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBenitec Biopharma Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBenitec Biopharma Inc

Active IndicationsN/A

Inactive IndicationsSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeN/A